Leticia Toledo-Sherman

Corporate Officer/Principal presso LymphoSign, Inc.

Commercial Services

Health Technology

Consumer Services

Profilo

Leticia Toledo-Sherman has been Executive Director of Chemistry for LymphoSign, Inc. since August 2004.
Prior to joining LymphoSign, Inc, she was Director of Drug Design and Discovery for MDS Proteomics Inc. Dr. Toledo-Sherman worked for Kinetix Pharmaceuticals, Inc. She received a PhD in Organic Chemistry from The State University of New York.

Posizioni attive di Leticia Toledo-Sherman

Società	Posizione	Inizio
LymphoSign, Inc. LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada.	Corporate Officer/Principal	01/08/2004

Tutte le posizioni attive di Leticia Toledo-Sherman

Precedenti posizioni note di Leticia Toledo-Sherman

Società	Posizione	Fine
MDS Proteomics, Inc.	Corporate Officer/Principal	-
Kinetix Pharmaceuticals, Inc. Kinetix Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kinetix Pharmaceuticals develops selective protein kinase inhibitors which block disease-causing pathways resulting from aberrant protein kinase activity	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Leticia Toledo-Sherman

Formazione di Leticia Toledo-Sherman

The State University of New York

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Leticia Toledo-Sherman

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	3
LymphoSign, Inc. LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada.	Health Technology
Kinetix Pharmaceuticals, Inc. Kinetix Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kinetix Pharmaceuticals develops selective protein kinase inhibitors which block disease-causing pathways resulting from aberrant protein kinase activity	Commercial Services
MDS Proteomics, Inc.	Commercial Services

Vedi le connessioni aziendali